Table 3 Results of repeat imaging at end of intended treatment period
Rivaroxaban 10 mg bid/15 mg od | Rivaroxaban 15 mg bid/15 mg od | Rivaroxaban combined | UFH/warfarin | |
|---|---|---|---|---|
DVT patients | N = 20 | N = 23 | N = 43 | N = 12 |
Improved or normalized, n (%) | 20 (100) | 20 (87.0) | 40 (93.0) | 11 (91.7) |
Normalized | 10 (50.0) | 10 (43.5) | 20 (46.5) | 4 (33.3) |
Unchanged, n (%) | 0 | 2 (8.7) | 2 (4.7) | 1 (8.3) |
Deteriorated, n (%) | 0 | 1 (4.3) | 1 (2.3) | 0 |
Asymptomatic | 0 | 0 | 0 | 0 |
Symptomatic* | 0 | 1 (4.3) | 1 (2.3) | 0 |
PE patients | - | N = 28 | N = 28 | N = 7 |
Improved or normalized, n (%) | - | 28 (100) | 28 (100) | 6 (85.7) |
Normalized | 24 (85.7) | 24 (85.7) | 2 (28.6) | |
Unchanged, n (%) | - | 0 | 0 | 0 |
Deteriorated, n (%) | - | 0 | 0 | 1 (14.3) |
Asymptomatic | 0 | 0 | 1 (14.3) | |
Symptomatic* | 0 | 0 | 0 | |
DVT and PE patients | N = 20 | N = 51 | N = 71 | N = 19 |
Improved or normalized, n (%) | 20 (100) | 48 (94.1) | 68 (95.8) | 17 (89.5) |
Normalized | 10 (50.0) | 34 (66.7) | 44 (62.0) | 6 (31.6) |
Unchanged, n (%) | 0 | 2 (3.9) | 2 (2.9) | 1 (5.3) |
Deteriorated, n (%) | 0 | 1 (2.0) | 1 (1.4) | 1 (5.3) |
Asymptomatic | 0 | 0 | 0 | 1 (5.3) |
Symptomatic* | 0 | 1 (2.0) | 1 (1.4) | 0 |